tirzepatide less side effects than semaglutide Cardiovascular outcomes of and for patients with type 2 diabetes in clinical practice Semaglutide vs Tirzepatide - Pro

L., Rosenbaum, M

Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Barbara H, Helen PH, James OH, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ

Non-alcoholic steatohepatitis shows promise following survodutides 47% resolution rate in Phase 2, and chronic kidney disease is emerging as a major downstream indication based on FLOW outcomes

( C ) Seahorse XFe24 traces of glucose oxidation, measured as the OCR by sequential injection of 20 mM glucose, 1 M oligomycin, 1 M FCCP [carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone], 1 M rotenone, and 2 M antimycin A into caSMCs cultured in normal (5.5 mmol/L) glucose media